PH12022500025A1 - Potent neutralizing antibodies against sars-cov-2, generation and uses thereof - Google Patents

Potent neutralizing antibodies against sars-cov-2, generation and uses thereof

Info

Publication number
PH12022500025A1
PH12022500025A1 PH1/2022/500025A PH12022500025A PH12022500025A1 PH 12022500025 A1 PH12022500025 A1 PH 12022500025A1 PH 12022500025 A PH12022500025 A PH 12022500025A PH 12022500025 A1 PH12022500025 A1 PH 12022500025A1
Authority
PH
Philippines
Prior art keywords
cov
generation
antibodies against
neutralizing antibodies
potent neutralizing
Prior art date
Application number
PH1/2022/500025A
Other languages
English (en)
Inventor
David D Ho
Yaoxing Huang
Lihong Liu
Yang Luo
Manoj S Nair
Pengfei Wang
Jian Yu
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of PH12022500025A1 publication Critical patent/PH12022500025A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH1/2022/500025A 2020-05-20 2021-05-20 Potent neutralizing antibodies against sars-cov-2, generation and uses thereof PH12022500025A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063027935P 2020-05-20 2020-05-20
US202063032518P 2020-05-29 2020-05-29
US202063039977P 2020-06-16 2020-06-16
US202063060116P 2020-08-02 2020-08-02
US202063063106P 2020-08-07 2020-08-07
US202063117908P 2020-11-24 2020-11-24
US202063123767P 2020-12-10 2020-12-10
US202163165729P 2021-03-24 2021-03-24
PCT/US2021/033512 WO2021236997A2 (en) 2020-05-20 2021-05-20 Potent neutralizing antibodies against sars-cov-2, generation and uses thereof

Publications (1)

Publication Number Publication Date
PH12022500025A1 true PH12022500025A1 (en) 2024-03-25

Family

ID=78707603

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/500025A PH12022500025A1 (en) 2020-05-20 2021-05-20 Potent neutralizing antibodies against sars-cov-2, generation and uses thereof

Country Status (13)

Country Link
US (3) US20230203134A1 (https=)
EP (1) EP4153625A4 (https=)
JP (1) JP2023526469A (https=)
KR (1) KR20230024904A (https=)
AU (1) AU2021277373A1 (https=)
BR (1) BR112022023467A2 (https=)
CA (1) CA3184184A1 (https=)
CL (1) CL2022003215A1 (https=)
CO (1) CO2022018192A2 (https=)
IL (1) IL298263A (https=)
MX (1) MX2022014420A (https=)
PH (1) PH12022500025A1 (https=)
WO (4) WO2021236997A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240182T1 (hr) 2020-03-26 2024-04-26 Vanderbilt University Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2)
EP4153625A4 (en) * 2020-05-20 2024-09-25 The Trustees Of Columbia University In The City Of New York STRONG NEUTRALISING ANTIBODIES AGAINST SARS-COV-2, THEIR PRODUCTION AND USE
WO2024089277A2 (en) * 2022-10-27 2024-05-02 Oxford University Innovation Limited Antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1778283A2 (en) * 2004-06-30 2007-05-02 ID Biomedical Corporation of Quebec Vaccine compositions for treating coronavirus infection
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
CA2662350A1 (en) * 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP2242768A4 (en) * 2008-01-17 2012-03-14 Humabs Llc CROSS-NEUTRALIZATION OF HUMAN MONOCLONAL ANTIBODIES AGAINST SARS-COV AND METHODS FOR THEIR APPLICATION
CN108610416B (zh) * 2008-10-13 2022-01-14 生物医学研究所 登革热病毒中和抗体及其用途
CA2742969A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
CA2932405A1 (en) * 2013-12-02 2015-06-11 Aaron Diamond Aids Research Center Improved hiv-1-neutralizing antibody potency and breadth via cell receptor anchoring using bispecific antibodies with native architecture
WO2016138160A1 (en) * 2015-02-24 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
WO2016187220A2 (en) * 2015-05-18 2016-11-24 Five Prime Therapeutics, Inc. Anti-ror1 antibodies
EP3356415B1 (en) * 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
CR20180365A (es) * 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
CN113056483B (zh) * 2018-07-09 2025-08-01 戊瑞治疗有限公司 结合到ilt4的抗体
EP4153625A4 (en) * 2020-05-20 2024-09-25 The Trustees Of Columbia University In The City Of New York STRONG NEUTRALISING ANTIBODIES AGAINST SARS-COV-2, THEIR PRODUCTION AND USE

Also Published As

Publication number Publication date
US20230203134A1 (en) 2023-06-29
AU2021277373A1 (en) 2023-01-05
WO2021236998A3 (en) 2021-12-16
CL2022003215A1 (es) 2023-07-07
CA3184184A1 (en) 2021-11-25
US20240002476A1 (en) 2024-01-04
BR112022023467A2 (pt) 2023-03-28
WO2021236995A3 (en) 2022-09-15
WO2021236998A2 (en) 2021-11-25
JP2023526469A (ja) 2023-06-21
EP4153625A4 (en) 2024-09-25
WO2021236997A3 (en) 2022-09-29
WO2021236996A3 (en) 2022-11-17
KR20230024904A (ko) 2023-02-21
MX2022014420A (es) 2023-03-21
IL298263A (en) 2023-01-01
WO2021236996A2 (en) 2021-11-25
WO2021236997A2 (en) 2021-11-25
CO2022018192A2 (es) 2023-03-17
WO2021236995A2 (en) 2021-11-25
EP4153625A2 (en) 2023-03-29
WO2021236998A9 (en) 2022-03-31
US20230203138A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
ZA202106131B (en) Bcma monoclonal antibody-drug conjugate
PH12022500025A1 (en) Potent neutralizing antibodies against sars-cov-2, generation and uses thereof
MX2023014458A (es) Anticuerpos anti-ccr8 y usos de los mismos.
EA201992469A1 (ru) Антигенспецифические иммунные эффекторные клетки
WO2021236980A8 (en) Coronavirus antigen compositions and their uses
WO2018237148A8 (en) Multispecific antibodies that target hiv gp120 and cd3
PE20141722A1 (es) Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
PH12020551948A1 (en) Monospecific and multispecific anti-tmeff2 antibodies and their uses
PH12019502475A1 (en) Transmitting method for synchronization signal, receiving method for synchronization signal, and related devices
ZA202309516B (en) Anti-ccr8 antibodies
WO2020247929A8 (en) High affinity anti-cd3 antibodies, and methods for their generation and use
ZA202211168B (en) Fragrance composition
MX2023005841A (es) Anticuerpos anti-marco y usos de estos.
PH12020500414A1 (en) Method for producing influenza ha split vaccine
ZA202402162B (en) Novel yhhs variant and method for producing o-phosphoserine, cysteine, and derivate of cysteine using same
ZA202402071B (en) Lyse variant and method for producing l-arginine by using same
ZA202303479B (en) Microorganism for producing putrescine and process for producing putrescine by using same
MY208974A (en) Method for preparing influenza ha split vaccine
MX2024001304A (es) Composiciones y metodos para anticuerpos anti-pacap.
EA201692175A1 (ru) Способ получения метанола
MY204177A (en) Method for producing influenza ha split vaccine
MX2024006261A (es) Composiciones inmunogenas de coronavirus y sus usos.
ZA202304932B (en) Microorganism having enhanced l-glutamine producing ability, and l-glutamine producing method using same
MX2023009568A (es) Materiales y métodos para el direccionamiento mejorado de enlazador.